Counteracting muscle wasting in HIV-infected individuals

HIV Medicine

Volumn 7, Issue 5, 2006, Pages 299-310

  Dudgeon, W D ^a   Phillips, K D ^a   Carson, J A ^a   Brewer, R B ^a   Durstine, J L ^a   Hand, G A ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

AIDS; Exercise; HIV; Muscle wasting

Indexed keywords

ANTIOXIDANT; ANTIRETROVIRUS AGENT; ARGININE; CYTOKINE; GLUTAMINE; GROWTH FACTOR; GROWTH HORMONE; HYDROCORTISONE; KETOTIFEN; NANDROLONE DECANOATE; PENTOXIFYLLINE; SOMATOMEDIN C; TESTOSTERONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACNE; ANOREXIA; ARTHRALGIA; BREAST TENDERNESS; CLINICAL TRIAL; DIARRHEA; DIET SUPPLEMENTATION; DISEASE COURSE; EDEMA; ENTEROPATHY; EXERCISE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGLYCEMIA; LOW DRUG DOSE; MALNUTRITION; META ANALYSIS; METABOLIC DISORDER; MORBIDITY; MYALGIA; NEUROLOGIC DISEASE; NONHUMAN; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; PATHOGENESIS; PHYSICAL DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STEATORRHEA; SYSTEMATIC REVIEW; TESTIS DISEASE; VOMITING; WASTING SYNDROME;

CYTOKINES; EXERCISE THERAPY; GROWTH HORMONE; HIV INFECTIONS; HIV WASTING SYNDROME; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALNUTRITION; MUSCULAR ATROPHY; NANDROLONE; TESTOSTERONE;

EID: 33744482887     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00380.x     Document Type: Review

References (99)

1. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 31: 803-805.
2. Coats AJ. Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath. Int J Cardiol 2002; 85: 133-139.
3. Clarys JP, Martin AD, Drinkwater DT. Gross tissue weights in the human body by cadaver dissection. Hum Biol 1984; 56: 459-473.
4. Snyder WS, Cook MJ, Nasset ES, Karhansen LR, Howells GP, Tipton IH. Report of the Task Group on the Reference Man. Oxford, UK: Pergamon, 1975.
5. Wheeler DA, Gibert CL, Launer CA et al. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 80-85.
6. Grinspoon S, Corcoran C, Rosenthal D et al. Quantitative assessment of cross-sectional muscle area, functional status, and muscle strength in men with the acquired immunodeficiency syndrome wasting syndrome. J Clin Endocrinol Metab 1999; 84: 201-206.
7. Schwenk A, Beisenherz A, Romer K, Kremer G, Salzberger B, Elia M. Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment. Am J Clin Nutr 2000; 72: 496-501.
8. Guenter P, Muurahainen N, Simons G et al. Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr 1993; 6: 1130-1138.
9. Kotler DP, Tierney AR, Want J, Pierson RN. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutrition 1989; 50: 444-447.
10. Rivera S, Briggs W, Qian D, Sattler FR. Levels of HIV RNA are quantitatively related to prior weight loss in HIV-associated wasting. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 411-418.
11. Golden MH, Waterlow JC, Picou D. Protein turnover, synthesis and breakdown before and after recovery from protein-energy malnutrition. Clin Sci Mol Med 1977; 53: 473-477.
12. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 2003; 5: 87-90.
13. Lane BJ, Provost-Craig MA. Resting energy expenditure in asymptomatic HIV-infected females. J Womens Health Gend Based Med 2000; 9: 321-327.
14. Grinspoon S, Corcoran C, Miller K et al. Determinants of increased energy expenditure in HIV-infected women. Am J Clin Nutr 1998; 68: 720-725.
15. Sharpstone D, Ross H, Hancock M, Phelan M, Crane R, Gazzard B. Indirect calorimetry, body composition and small bowel function in asymptomatic HIV-seropositive women. Int J STD AIDS 1997; 8: 700-703.
16. Shevitz AH, Knox TA, Spiegelman D, Roubenoff R, Gorbach SL, Skolnik PR. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS 1999; 13: 1351-1357.
17. Suttmann U, Holtmannspotter M, Ockenga J, Gallati H, Deicher H, Selberg O. Tumor necrosis factor, interleukin-6, and epinephrine are associated with hypermetabolism in AIDS patients with acute opportunistic infections. Ann Nutr Metab 2000; 44: 43-53.
18. Sharpstone D, Ross H, Hancock M, Phelan M, Crane R, Gazzard B. Indirect calorimetry, body composition and small bowel function in asymptomatic HIV-seropositive women. Int J STD AIDS 1997; 8: 700-703.
19. Kosmiski LA, Kuritzkes DR, Lichtenstein KA et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 2001; 15: 1993-2000.
20. Edwards P, Wodak A, Cooper DA, Thompson IL, Penny R. The gastrointestinal manifestations of AIDS. Aust N Z J Med 1990; 20: 141-148.
21. Monkemuller KE, Call SA, Lazenby AJ, Wilcox CM. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy. Am J Gastroenterol 2000; 95: 457-462.
22. Ceballos-Salobrena A, Gaitan-Cepeda LA, Ceballos-Garcia L, Lezama-Del Valle D. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: A new face of oral AIDS? AIDS Patient Care STDS 2000; 14: 627-635.
23. Younai FS, Marcus M, Freed JR et al. Self-reported oral dryness and HIV disease in a national sample of patients receiving medical care. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 629-636.
24. Zeitz M, Ullrich R, Schneider T, Kewenig S, Riecken E. Mucosal immunodeficiency in HIV/SIV infection. Pathobiology 1998; 66: 151-157.
25. Sharpstone D, Neild P, Crane R et al. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut 1999; 45: 70-76.
26. Batman PA, Kapembwa MS, Miller AR et al. HIV enteropathy: Comparative morphometry of the jejunal mucosa of HIV infected patients resident in the United Kingdom and Uganda. Gut 1998; 43: 350-355.
27. Carroccio A, Guarino A, Zuin G et al. Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients. Aliment Pharmacol Ther 2001; 15: 1619-1625.
28. Shimomura S, Kikuchi Y, Oka S, Ishitoya J. Local treatment of AIDS-associated bulky Kaposi's sarcoma in the head and neck region. Auris Nasus Larynx 2000; 27: 335-338.
29. Roubenoff R. Acquired immunodeficiency syndrome wasting, functional performance, and quality of life. Am J Manag Care 2000; 6: 1003-1016.
30. Razani J, Murphy C, Davidson TM, Grant I, McCutchan A. Odor sensitivity is impaired in HIV-positive cognitively impaired patients. Physiol Behav 1996; 59: 877-881.
31. Merrill A. AIDS and malnutrition: Dual assaults on the body. Home Healthc Nurse 1995; 13: 56-60.
32. Heald AE, Pieper CF, Schiffman SS. Taste and smell complaints in HIV-infected patients. AIDS 1998; 12: 1667-1674.
33. Wulff EA, Wang AK, Simpson DM. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 2000; 59: 1251-1260.
34. Moldawer LL, Sattler FR. Human immunodeficiency virus-associated wasting and mechanisms of cachexia associated with inflammation. Semin Oncol 1998; 25 (Suppl. 1): 73-81.
35. Tisdale MJ. Wasting in cancer. J Nutr 1999; 129 (Suppl. 1S): 243S-246S.
36. Farber MO, Mannix ET. Tissue wasting in patients with chronic obstructive pulmonary disease. Neurol Clin 2000; 18: 245-262.
37. Anker SD, Rauchhaus M. Insights into the pathogenesis of chronic heart failure: Immune activation and cachexia. Curr Opin Cardiol 1999; 14: 211-216.
38. Reid MB, Li YP. Tumor necrosis factor-alpha and muscle wasting: A cellular perspective. Respir Res 2001; 2: 269-272.
39. Li X, Youngblood GL, Payne AH, Hales DB. Tumor necrosis factor-alpha inhibition of 17 alpha-hydroxylase/C17-20 lyase gene (Cyp17) expression. Endocrinology 1995; 136: 3519-3526.
40. Suttman U, Selberg O, Gallati H, Ockenga J, Deicher H, Muller MJ. Tumour necrosis factor receptor levels are linked to the acute-phase response and malnutrition in human-immunodeficiency-virus infected patients. Clin Sci 1994; 86: 461-467.
41. Roubenoff R, Grinspoon S, Skolnik PR et al. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men. Am J Physiol Endocrinol Metab 2002; 283: E138-E145.
42. Gorman JM, Kertzner R, Cooper T et al. Glucocorticoid level and neuropsychiatric symptoms in homosexual men with HIV infection. Am J Psychiatry 1991; 148: 41-45.
43. Breitkreutz R, Wagner J, Tokus M et al. Flux of amino acids and energy substrates across the leg in weight-stable HIV-infected patients with acute opportunistic infections: Indication of a slow protein wasting process. J Mol Med 2001; 79: 671-678.
44. Crown AL, He XL, Holly JM, Lightman SL, Stewart CE. Characterisation of the IGF system in a primary adult human skeletal muscle cell model, and comparison of the effects of insulin and IGF-I on protein metabolism. J Endocrinol 2000; 167: 403-415.
45. Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SD. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol 2003; 547: 247-254.
46. Grinspoon S, Corcoran C, Lee K et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 1996; 81: 4051-4058.
47. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998; 140: 19-24.
48. Frost RA, Fuhrer J, Steigbigel R, Mariuz P, Lang CH, Gelato MC. Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Clin Endocrinol (Oxf) 1996; 44: 501-514.
49. Dobs AS. Androgen therapy in AIDS wasting. Baillieres Clin Endocrinol Metab 1998; 12: 379-390.
50. Griggs RC, Halliday D, Kingston W, Moxley RT III. Effect of testosterone on muscle protein synthesis in myotonic dystrophy. Ann Neurol 1986; 20: 590-596.
51. Urban RJ, Bodenburg YH, Gilkison C et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269: E820-E826.
52. Wu FC. Endocrine aspects of anabolic steroids. Clin Chem 1997; 43: 1289-1292.
53. Schwenk A, Steuck H, Kremer G. Oral supplements as adjunctive treatment to nutritional counseling in malnourished HIV-infected patients: randomized controlled trial. Clin Nutr 1999; 18: 371-374.
54. Charlin V, Carrasco F, Sepulveda C, Torres M, Kehr J. Nutritional supplementation according to energy and protein requirements in malnourished HIV-infected patients. Arch Latinoam Nutr 2002; 52: 267-273.
55. Kotler DP, Tierney AR, Culpepper-Morgan JA, Wang J, Pierson RN Jr. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. J Parenter Enteral Nutr 1990; 14: 454-458.
56. Shabert JK, Wilmore DW. Glutamine deficiency as a cause of human immunodeficiency virus wasting. Med Hypotheses 1996; 46: 252-256.
57. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327: 329-337.
58. Shabert JK, Winslow C, Lacey JM, Wilmore DW. Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: A randomized, double-blind controlled trial. Nutrition 1999; 15: 860-864.
59. Clark RH, Feleke G, Din M et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: A randomized, double-blind, placebo-controlled study. JPEN J Parenter Enteral Nutr 2000; 24: 133-139.
60. Nissen S, Sharp R, Ray M et al. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. J Appl Physiol 1996; 81: 2095-2104.
61. Sitren HS, Fisher H. Nitrogen retention in rats fed on diets enriched with arginine and glycine. 1. Improved N retention after trauma. Br J Nutr 1977; 37: 195-208.
62. Snyder PJ, Peachey H, Berlin JA et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670-2677.
63. Svartberg J, Aasebo U, Hjalmarsen A, Sundsfjord J, Jorde R. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 2004; 98: 906-913.
64. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156: 1173-1177.
65. Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis 2002; 2: 692-699.
66. Miller K, Corcoran C, Armstrong C et al. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab 1998; 83: 2717-2725.
67. Grinspoon S, Corcoran C, Parlman K et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 2000; 133: 348-355.
68. Bhasin S, Storer TW, Javanbakht M et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. J Am Med Assoc 2000; 283: 763-770.
69. Coodley GO, Coodley MK. A trial of testosterone therapy for HIV-associated weight loss1. AIDS 1997; 11: 1347-1352.
70. Grinspoon S, Corcoran C, Anderson E et al. Sustained anabolic effects of long-term androgen administration in men with AIDS wasting. Clin Infect Dis 1999; 28: 634-636.
71. Sattler FR, Jaque SV, Schroeder ET et al. Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. J Clin Endocrinol Metab 1999; 84: 1268-1276.
72. Strawford A, Barbieri T, Neese R et al. Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 137-146.
73. Gold J, High HA, Li Y et al. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 1996; 10: 745-752.
74. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 77: 956-962.
75. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
76. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 508-510.
77. Waters D, Danska J, Hardy K et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125: 865-872.
78. Schambelan M, Mulligan K, Grunfeld C et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996; 125: 873-882.
79. Tai VW, Schambelan M, Algren H, Shayevich C, Mulligan K. Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin Infect Dis 2002; 35: 1258-1262.
80. Lo JC, Mulligan K, Noor MA et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001; 86: 3480-3487.
81. Engelson ES, Glesby MJ, Mendez D et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr 2002; 30: 379-391.
82. Mulligan K, Tai VW, Schambelan M. Use of growth hormone and other anabolic agents in AIDS wasting. JPEN J Parenter Enteral Nutr 1999; 23 (Suppl.): S202-S209.
83. Lee PD, Pivarnik JM, Bukar JG et al. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1996; 81: 2968-2975.
84. Ellis KJ, Lee PD, Pivarnik JM, Bukar JG, Gesundheit N. Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor I and growth hormone. J Clin Endocrinol Metab 1996; 81: 3033-3038.
85. Spate U, Schulze PC. Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr Metab Care 2004; 7: 265-269.
86. Gelato MC, Mynarcik D, McNurlan MA. Soluble tumour necrosis factor alpha receptor 2, a serum marker of resistance to the anabolic actions of growth hormone in subjects with HIV disease. Clin Sci (Lond) 2002; 102: 85-90.
87. Kaplan G, Thomas S, Fierer DS et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000; 16: 1345-1355.
88. Reyes-Teran G, Sierra-Madero JG, Martinez dC et al. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial. AIDS 1996; 10: 1501-1507.
89. Haslett P, Hempstead M, Seidman C et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 1997; 13: 1047-1054.
90. Dezube BJ, Lederman MM, Spritzler JG et al. High-dose pentoxifylline in patients with AIDS: Inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. J Infect Dis 1995; 171: 1628-1632.
91. Ockenga J, Rohde F, Suttmann U, Herbarth L, Ballmaier M, Schedel I. Ketotifen in HIV-infected patients: Effects on body weight and release of TNF-alpha. Eur J Clin Pharmacol 1996; 50: 167-170.
92. Hurley BF, Redmond RA, Pratley RE, Treuth MS, Rogers MA, Goldberg AP. Effects of strength training on muscle hypertrophy and muscle cell disruption in older men. Int J Sports Med 1995; 16: 378-384.
93. Tipton KD, Wolfe RR. Exercise, protein metabolism, and muscle growth. Int J Sport Nutr Exerc Metab 2001; 11: 109-132.
94. Castaneda C, Gordon PL, Uhlin KL et al. Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial. Ann Intern Med 2001; 135: 965-976.
95. Hakkinen A, Sokka T, Kotaniemi A, Hannonen P. A randomized two-year study of the effects of dynamic strength training on muscle strength, disease activity, functional capacity, and bone mineral density in early rheumatoid arthritis. Arthritis Rheum 2001; 44: 515-522.
96. Bopp CM, Phillips KD, Fulk LJ, Hand GA. Clinical implications of therapeutic exercise in HIV/AIDS. J Assoc Nurses AIDS Care 2003; 14: 73-78.
97. Dudgeon WD, Phillips KD, Bopp CM, Hand GA. Physiological and psychological effects of exercise interventions in HIV disease. AIDS Patient Care STDS 2004; 18: 81-98.
98. Roubenoff R, McDermott A, Weiss L et al. Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus. AIDS 1999; 13: 231-239.
99. Roubenoff R, Wilson IB. Effect of resistance training on self-reported physical functioning in HIV infection. Med Sci Sports Exerc 2001; 33: 1811-1817.